We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
-12.3%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$784M
AUM Growth
-$237M
Cap. Flow
-$21M
Cap. Flow %
-2.67%
Top 10 Hldgs %
46.1%
Holding
163
New
33
Increased
30
Reduced
43
Closed
36

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$37.3M
2
INCY icon
Incyte
INCY
+$11.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.68M
4
SHPG
Shire pic
SHPG
+$8.32M
5
BIIB icon
Biogen
BIIB
+$8.01M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$22.8M
2
GILD icon
Gilead Sciences
GILD
+$22.2M
3
PFE icon
Pfizer
PFE
+$10.1M
4
CXRX
Concordia International Corp. Common Stock
CXRX
+$9.03M
5
VRNT
Verint Systems
VRNT
+$8.47M

Sector Composition

Rank Sector Weight
1 Healthcare 59.24%
2 Miscellaneous 30%
3 Industrials 4.06%
4 Utilities 2.54%
5 Communication Services 1.52%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NDRM
101
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.76M 0.22%
+85,000
New +$1.74M
PANW icon
102
Palo Alto Networks
PANW
$307B
$1.72M 0.22%
+60,012
New +$1.77M
NBRV
103
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$1.66M 0.21%
+700
New +$1.86M
PVLA
104
Palvella Therapeutics
PVLA
$2.22B
$1.65M 0.21%
11,250
-3,750
-25% -$837K
ZGNX
105
DELISTED
Zogenix, Inc.
ZGNX
$1.62M 0.21%
+120,000
New +$2.16M
ARRY
106
DELISTED
Array Biopharma Inc
ARRY
$1.6M 0.2%
350,000
-450,000
-56% -$2.67M
OCRX
107
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.58M 0.2%
+500,000
New +$1.92M
ALDX icon
108
Aldeyra Therapeutics
ALDX
$83.3M
$1.54M 0.2%
265,000
– –
KALV
109
DELISTED
KalVista Pharmaceuticals
KALV
$1.43M 0.18%
28,571
– –
MRNS
110
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.35M 0.17%
40,530
-34,103
-46% -$1.92M
TBRA
111
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$1.33M 0.17%
137,622
– –
LRMR icon
112
Larimar Therapeutics
LRMR
$395M
$1.28M 0.16%
+3,333
New +$1.5M
CLCD
113
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$1.23M 0.16%
317,250
– –
HRTX icon
114
Heron Therapeutics
HRTX
$59.9M
$1.22M 0.16%
+50,000
New +$1.67M
ORBK
115
DELISTED
Orbotech Ltd
ORBK
$1.21M 0.15%
78,482
-136,440
-63% -$2.38M
ANAC
116
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$1.18M 0.15%
+10,000
New +$1.31M
NVAX icon
117
Novavax
NVAX
$1.65B
$1.06M 0.14%
+7,500
New +$1.68M
AXTA icon
118
Axalta
AXTA
$6.98B
$1.03M 0.13%
+40,626
New +$1.21M
WIX icon
119
WIX.com
WIX
$3.34B
$1.01M 0.13%
58,160
-62,145
-52% -$1.39M
GNVC
120
DELISTED
GenVec, Inc.
GNVC
$832K 0.11%
36,033
– –
CHTR icon
121
Charter Communications
CHTR
$15.3B
$708K 0.09%
4,026
-6,039
-60% -$1.1M
APTV icon
122
Aptiv
APTV
$9.06B
$696K 0.09%
9,150
-43,920
-83% -$3.38M
AOS icon
123
A.O. Smith
AOS
$7.74B
$681K 0.09%
20,882
-80,358
-79% -$2.75M
SAGE
124
DELISTED
Sage Therapeutics
SAGE
$339K 0.04%
8,000
-40,000
-83% -$2.47M
NICE icon
125
Nice
NICE
$6.17B
$255K 0.03%
4,525
-13,725
-75% -$857K
3 4
5
6 7

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q3 2015 Portfolio in Review

As of Q3 2015, Sphera Funds Management held 163 positions worth $784M, down 23% from $1.02B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Sphera Funds Management's Q3 2015 filing shows 33 new, 30 increased, 43 reduced and 36 closed positions. Its largest new stake was Incyte: 100,000 shares worth $11M. The largest sale was Merck, an estimated $22.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 55% a quarter earlier, followed by Miscellaneous and Industrials.

  • Sphera Funds Management's largest Q3 2015 buy was Incyte: 100,000 shares worth $11M.
  • Sphera Funds Management added most to Teva Pharmaceutical Industries Limited in Q3 2015, an estimated $37.3M increase.
  • Sphera Funds Management's biggest Q3 2015 reduction was Gilead Sciences, cutting an estimated $22.2M.
  • Sphera Funds Management fully exited Merck in Q3 2015, selling an estimated $22.8M.
  • Sphera Funds Management's ten largest holdings make up 46% of its $784M portfolio in Q3 2015.
  • Sphera Funds Management opened 33 new positions and closed 36 in Q3 2015.
  • Sphera Funds Management's portfolio value fell 23% quarter-over-quarter to $784M.

Based on Sphera Funds Management's 13F filing for Q3 2015, filed 16 Nov 2015.